Pharmaceuticals Company

Savoy Pharmaceuticals

100%

Funding Goal $2,500,000
Funding Raised So Far $2,500,000
Funding Commitments $0
Funding Remaining $0
Funding Type Equity
Pre-Money Valuation
Investor Ownership
Interest / Dividend
Previous Funding

Company Overview


Savoy Pharmaceuticals, founded in 2004, is working to bring more effective and safer therapies to cancer patients by developing targeted, immunotherapies using the human immune system to treat cancers and viruses.

Funded by $2.5M in private investment, Savoy has only $600k in equity capital remaining and available to investors before the series A capital raise closes. Savoy has completed pre-clinical, IND enabling studies and is preparing to enter clinical trials for 2 of its 30+ indications. This investment will fund the remaining development of the antibody to take into clinical trials.

According to a new study by the IMS Institute for Healthcare Informatics, global oncology spending hit $91 billion last year, and it's growing 5% annually. The overall cost for cancer treatments per month in the U.S. is now $10,000, up from $5,000 just a year ago. With new cancer diagnosis reaching a projected $2B in 2020, pancreas and liver cancers are projected to surpass breast, prostate, and colorectal cancers to become the second and third leading causes of cancer-related death by 2030.

In the search for targeted therapies many scientists have turned to blood serum in the hope of identifying a chemical marker that could allow simple and accurate treatment of cancer.Like most research, those markers discovered have provided only limited success.

In pre-clinical trials, Savoy's patented novel tumor marker was found on the surface of several cancer types as well as viruses in large enough quantity to make it a viable marker for antibodies to solicit the immune system, killing cancer cells while leaving normal cells unharmed. Currently unprecedented to find a marker consistent on several different types of cancer, this finding could change the way we look at treating cancer and reduce the need for chemotherapy. Savoy is comprised of a team of MD’s, Scientists and MBA's with backgrounds from UCLA, University of Rochester, BYU, MD Anderson, Roche, and Genentech.

Read More
lock icon

Unlock Company Profile

Sign up now to unlock full company profiles and access financials, investor documents, and engage companies.

Business Summary


Company Age 17 years, 8 months
Employees 30
Sub-Industry Other Pharmaceuticals
Prior Year Revenue
Current Year Revenue
Next Year Revenue

Products/Services


Oncoprev

Oncoprev is a humanized monoclonal antibody that specifically targets cancer cells for destruction by attaching to our novel tumor marker, TK1, while leaving normal cells unharmed for the safe and effective treatment of liver, pancreatic, breast, colon, bladder, thyroid, skin, and cervical cancer.

Management


Nathaniel Lallatin, MBA
President Executive Officer
Nathaniel Lallatin, MBA

Nathaniel is a successful entrepreneur who has experience working for both large pharmaceutical companies and start-ups. Nathaniel’s prior positions include: Co-founder of Celtic Biotech, Corporate Development at Fisher Scientific and Idaho Technology, Inc. (a subsidiary of Roche Diagnostics), Merchant Banker at Latona Associates, Nathaniel’s accomplishments include: Developing strategies to acquire key competitors and products, Leading the scientific arm of Fisher Scientifics acquisition of PSS World Medical for $840M, and acquisition of Cole-Parmer Instrument Company for $205M. Nathaniel received his MBA from the University of Rochester Simon School of Business Administration and a second MBA from the SDA Bocconi in Milan, Italy. Nathaniel studied Immunology at the UCLA School of Medicine MD/Ph. D.

Gerald Lallatin, Esq.
Managing Director Financial Officer
Gerald Lallatin, Esq.

Gerald attended the BYU School of Law J.D. Previously he was Chief Financial Officer and Senior Vice President of Idaho Bank and Trust; and Chief Financial Officer of IB&T Corp. CPA with the firm of Ernst & Ernst specializing in audits and management consulting for regional corporations. At the law firm of Richards, Brandt, Miller & Nelson, he provided legal services to a major corporation related to acquisitions. He is a founding partner of the law firm of Dredge & Lallatin in Provo, Utah, and is currently counsel to the firm.

Sofia Lallatin
Director Business Development
Sofia Lallatin

Sofia brings 10 years of experience in sales, marketing, and corporate training. She has successfully opened new markets and grown them to outperform existing markets as a sales executive. Sofia manages investor relations, capital raising campaigns, and contracted services.

100%

Funding Goal $2,500,000
Funding Raised So Far $2,500,000
Funding Commitments $0
Funding Remaining $0
Funding Type Equity
Pre-Money Valuation
Investor Ownership
Interest / Dividend
Previous Funding

Documents


Contact


Savoy Pharmaceuticals

Salt Lake City, UT 84121, US

Top 10 Tips for Entrepreneurs Seeking Funding

Users who follow these tips increase their fundraising odds substantially.

  • Complete Your Funding Profile
    • Complete your funding profile with all sections filled, including your products and services, a complete management team with headshots, and slideshow with product images.
  • Complete a Business Plan
    • Complete a Business Plan in EquityNet and refine your financial projections using the benchmarking alerts in the Business Plan Analysis report.
  • Upload Important Investment Documents
    • Upload and present any other important investment documents such as pitch decks, financial statements, and offering materials.
  • Use EquityNet Crowdcast
    • Use the EquityNet Crowdcast system to automatically email invitations to your contacts in order to build additional exposure for your company.
  • Construct Concise Introductory Messages
    • Construct and send a concise introductory message to investors, including primary reasons why they should want to invest such as KPIs, expected returns, and forecasted revenue.
  • Be Proactive in Messaging Investors
    • Be proactive in messaging many investors and include a simple way for them to connect with you for a web meeting or call, such as a Calendly link.
  • Use the Activity System
    • Use the Activity system to track interested investors, and send prompt follow-up messages to investors who viewed your profile or showed interest.
  • Prepare for Due Diligence
    • Prepare for due diligence questions by interested investors and use your Business Plan and investment documents to satisfy such requests.
  • Keep Your Funding Profile Updated
    • Keep your funding profile updated with new funding raised/committed and message interested investors with any new milestones achieved.
  • Do Not Respond to Unknown Investors
    • Do not respond to or engage any parties outside of EquityNet that are not listed as approved investors (this may happen due to your public profile and LinkedIn connections).